{"product_id":"dynavax-marketing-mix","title":"Dynavax Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDynavax leverages targeted product positioning in vaccines, value-based pricing, specialized distribution channels, and focused scientific promotion to reach healthcare stakeholders and payers; the preview highlights strategic alignment and market leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV-B Adult Hepatitis B Vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHEPLISAV-B is Dynavax’s flagship as of late 2025, the only adult hepatitis B vaccine given in two doses one month apart, driving 2024 US net sales of about $210M and contributing \u0026gt;60% of product revenues.\u003c\/p\u003e\n\u003cp\u003eIt uses CpG 1018 adjuvant (proprietary) to deliver higher seroprotection—meta-analyses show 90–95% rates vs ~75–85% for traditional three-dose vaccines in adults.\u003c\/p\u003e\n\u003cp\u003eTargeting adults, esp. people with diabetes and those needing rapid immunization, HEPLISAV-B shortens series completion time, reducing drop-off risk by an estimated 25–35% versus three-dose schedules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCpG 1018 Adjuvant Supply and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax sells its proprietary Toll-like receptor 9 agonist CpG 1018 as a B2B adjuvant, licensing it to global vaccine developers and supplying GMP material; revenues from CpG 1018 licensing and supply contributed roughly $45–60 million annually by 2024, with guidance expecting growth as partners expand programs.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 CpG 1018 is integrated into multiple partner programs for infectious diseases beyond hepatitis B, including respiratory and emerging-pathogen candidates, representing at least 6 confirmed collaborations and several preclinical deals.\u003c\/p\u003e\n\u003cp\u003eThis offering diversifies Dynavax revenue away from hepatitis B vaccine sales, lowers concentration risk, and positions the company as critical vaccine infrastructure, supporting margin accretion from high-value licensing and supply contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Pipeline Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax’s clinical pipeline includes a Tdap booster candidate and a shingles (herpes zoster) program leveraging CpG 1018 adjuvant to raise antibody titers versus current vaccines; phase 2\/3 activity targets \u0026gt;50% higher neutralizing responses seen in prior CpG trials. R\u0026amp;D prioritizes respiratory and shingles unmet needs in adults 60+, where herpes zoster incidence is ~10 per 1,000 person-years and COPD-related vaccine gaps drive market demand estimated at $4–6B by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax operates a GMP-certified manufacturing and quality control site in Düsseldorf, Germany, producing the CpG 1018 adjuvant and finished vaccines with capacity to supply partners and internal programs; in 2024 the plant supported \u0026gt;50 million adjuvant doses and passed EMA-aligned quality audits.\u003c\/p\u003e\n\u003cp\u003eThis on-site capability boosts supply-chain reliability, meets global regulatory standards (EMA\/US FDA), and allows scalable output—capacity expansion plans target a 30% increase by end-2025 to support contract manufacturing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP site: Düsseldorf, Germany\u003c\/li\u003e\n\u003cli\u003e2024 output: \u0026gt;50M adjuvant doses\u003c\/li\u003e\n\u003cli\u003eRegulatory alignment: EMA and US FDA\u003c\/li\u003e\n\u003cli\u003ePlanned capacity +30% by 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjuvant Technology Platform Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax sells its adjuvant as a modular platform for pandemic preparedness and immunotherapy, letting partners plug it into new vaccine candidates beyond specific products.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the platform enables rapid pivoting to support formulations for emerging viruses; Dynavax reported platform-related licensing revenue of $45m in 2024 and expects \u0026gt;20% CAGR in platform deals through 2027.\u003c\/p\u003e\n\u003cp\u003eThis strategic flexibility raises IP value, supports recurring royalties, and reduces time-to-clinic for partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform licensing revenue $45m (2024)\u003c\/li\u003e\n\u003cli\u003eProjected platform deal CAGR \u0026gt;20% (2025–27)\u003c\/li\u003e\n\u003cli\u003eReduces partner time-to-clinic by months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV‑B $210M; CpG1018 boosts protection to 90–95%—supply \u0026gt;50M doses, capacity rising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHEPLISAV-B (2-dose adult hepB) drove ~ $210M US net sales in 2024; CpG 1018 adjuvant gives 90–95% seroprotection vs 75–85% for 3-dose; CpG licensing\/supply ~$45–60M in 2024 with \u0026gt;20% platform CAGR through 2027; Düsseldorf GMP: \u0026gt;50M adjuvant doses (2024), capacity +30% by end-2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEPLISAV-B 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCpG 1018 revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$45–60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeroprotection\u003c\/td\u003e\n\u003ctd\u003e90–95% vs 75–85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDüsseldorf output 2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50M doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Dynavax’s Product, Price, Place, and Promotion strategies—ideal for managers, consultants, and marketers needing a clear breakdown of the company’s marketing positioning grounded in real practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Dynavax’s 4P marketing strategy into a concise, at-a-glance summary that clarifies product positioning, pricing strategy, distribution touchpoints, and promotional levers—ideal for leadership briefings or rapid alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. Commercial Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary U.S. commercial channel for HEPLISAV-B is an internal specialty sales force targeting large health systems, integrated delivery networks, and major retail pharmacy chains where 70%+ of adult vaccines are given; the team covers ~1,200 high-priority accounts nationwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesaler and Distributor Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax uses major wholesalers AmerisourceBergen, Cardinal Health, and McKesson to distribute HEPLISAV-B across the US, leveraging their combined reach to supply ~90% of US hospitals and 85% of retail pharmacies as of 2024.\u003c\/p\u003e\n\u003cp\u003eThese partners provide validated cold-chain logistics, reducing temperature excursions to under 0.5% annually and cutting stock-out events by ~40% versus single-distributor models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Partnership Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor markets outside the United States, Dynavax Pharmaceuticals uses regional partnerships and licensing deals to overcome regulatory and distribution barriers; by end-2025 these collaborations in Europe and Asia cover over 22 countries and aim to increase international revenue to an estimated $85–95M, while avoiding the fixed costs of a global direct sales force. Partners contribute local regulatory expertise and logistics networks, cutting time-to-market by an average 6–9 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy and Clinic Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax relies on retail pharmacy and clinic integration as a key Place: by 2025 roughly 60% of adult hepatitis B vaccinations occur in pharmacies, so HEPLISAV-B placements at chains like CVS and Walgreens make it the accessible choice for walk-ins who skip doctor offices.\u003c\/p\u003e\n\u003cp\u003eThese partnerships boost reach—CVS and Walgreens together serve over 40,000 locations nationwide—supporting point-of-care uptake and incremental revenue from retail channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% adult HBV vaccinations at pharmacies (2025)\u003c\/li\u003e\n\u003cli\u003eCVS + Walgreens ≈ 40,000 locations\u003c\/li\u003e\n\u003cli\u003eWalk-in access increases capture of non–office patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax secures federal supply schedule placements and engages CDC procurement talks to supply public clinics, supporting state immunization programs that reach elderly and underserved groups; in 2024 public-sector channels accounted for roughly 35% of its HEPLISAV-B revenue, helping preserve market share amid ACIP recommendations and seasonal mandates.\u003c\/p\u003e \n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% of HEPLISAV-B 2024 revenue from public channels\u003c\/li\u003e\n\u003cli\u003eFederal schedule placement ensures clinic access\u003c\/li\u003e\n\u003cli\u003eSupports state programs targeting high-risk groups\u003c\/li\u003e\n\u003cli\u003eCritical for maintaining market share during mandates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV‑B: 1,200 reps, 90% hospital \u0026amp; 85% pharmacy reach—$85–95M intl target 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePlace: HEPLISAV-B sells via a 1,200-account specialty sales force, major wholesalers (AmerisourceBergen, Cardinal, McKesson) covering ~90% hospitals\/85% pharmacies, CVS+Walgreens ~40,000 locations, pharmacies ~60% of adult HBV shots (2025), public channels ~35% of 2024 revenue, international partners in 22+ countries targeting $85–95M by 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales force accounts\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital coverage\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy coverage\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCVS+Walgreens locations\u003c\/td\u003e\n\u003ctd\u003e~40,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy share (adult HBV, 2025)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic-channel revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational reach (end-2025)\u003c\/td\u003e\n\u003ctd\u003e22+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue target (2025)\u003c\/td\u003e\n\u003ctd\u003e$85–95M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eDynavax 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Dynavax 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749923402105,"sku":"dynavax-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dynavax-marketing-mix.png?v=1772220304","url":"https:\/\/matrixbcg.com\/products\/dynavax-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}